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Abstract
Background: Neurosarcoidosis is a rare variant of sarcoidosis and is only described in small cohort studies. We
define clinical features, treatment and outcome of patients with neurosarcoidosis over the last 35 years.
Methods: We performed a systematic review and meta-analysis of studies on neurosarcoidosis published between
1980 and 2016. Studies were included if they reported at least 5 cases. Studies describing one specific neurological
presentation were excluded.
Results: We identified 29 articles describing 1088 patients diagnosed between 1965 and 2015. Neurosarcoidosis
occurred in 5% of patients with systemic sarcoidosis. Mean age at presentation was 43 years and neurological
symptoms were the first clinical manifestation of sarcoidosis in 52%. The most commonly reported feature of
neurosarcoidosis was cranial neuropathy in 55%, with the facial and optic nerve most commonly affected, followed
by headache in 32%. Pleiocytosis and elevated CSF protein were found in 58 and 63%. MRI of the brain showed
abnormalities in 70%. Chest X-ray, chest CT, or gallium-67-scintigraphy showed findings consistent with sarcoidosis
in 60%, 70% and 69%, respectively. First line therapy with corticosteroids was initiated in 434 of 539 patients (81%).
Second and third line therapy was started in 27 and 9%. Outcome consisted of complete remission in 27%,
incomplete remission in 32%, stable disease in 24%, deterioration in 6% and death in 5%.
Conclusion: Neurosarcoidosis has a heterogeneous clinical presentation and the diagnosis can be difficult because
of low sensitivity of ancillary investigations. New treatments have emerged, but nevertheless one third of patients
do not respond to treatment. Prospective cohort studies and RCTs on treatment are urgently needed.
Keywords: Neurosarcoidosis, Clinical neurology, Auto-immune disease, Systemic disease, Systematic review, Meta-
analysis
Background
Sarcoidosis is a multisystem granulomatous inflamma-
tory disease of unknown aetiology, that typically affects
young adults [1]. The incidence varies throughout the
world, but is estimated to be between 10 and 20 per
100.000 population [2]. It mainly affects lung, skin and
eyes, and has been reported to involve the nervous sys-
tem in 5–20% [3, 4]. Neurologic manifestations de-
scribed are cranial nerve palsy, aseptic meningitis,
peripheral neuropathy and myopathy [5]. Data on
neurosarcoidosis are mostly derived from single-centre
retrospective studies and vary considerably between
studies [6]. Treatment is based on expert opinion, and
no randomized controlled trials have been done compar-
ing treatment in patients with neurosarcoidosis [7].
Diagnostic criteria for neurosarcoidosis have been pro-
posed based on a clinical presentation suggestive of neuro-
sarcoidosis, results of ancillary investigation and exclusion
of other diagnoses [5, 8–10]. A definite diagnosis of neuro-
sarcoidosis is met in only a minority of patients because
this needs histologic confirmation of non-caseating granu-
lomas of affected nervous system tissue. A probable diagno-
sis is defined as evidence of nervous system inflammation
on magnetic resonance imaging (MRI) or cerebrospinal
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fluid (CSF; elevated protein, cells, immunoglobin G indices,
or presence of oligoclonal bands) in combination with
evidence of systemic sarcoidosis with histological confirm-
ation and/or at least two of the indirect indicators
consisting of fluorodeoxyglucose positron emission
tomography (FDG-PET), gallium scan, chest imaging,
and serum angiotensin-converting enzyme. Possible
neurosarcoidosis is defined a clinical suspicion and
exclusion of other diagnoses, but above mentioned criteria
are not met.
We performed a systematic review and meta-analysis
to determine clinical features, treatment, and outcome
of patients with neurosarcoidosis over the last 35 years.
Methods
PubMed and Embase were searched using the search
terms “neurosarcoidosis”, “sarcoidosis” and “nervous
system”. Studies written in Dutch, English, French,
German, or Spanish published between 1980 and March
2016 were considered for inclusion. Studies were in-
cluded in the meta-analysis if they reported at least 5
cases of neurosarcoidosis, involving at least intracranial
manifestations other than isolated hypothalamo-pituitary
neurosarcoidosis. Studies were excluded if they: 1) reported
only on a specific subset of neurosarcoidosis manifestations
(e.g., neuro-ophthalmic or spinal cord neurosarcoidosis); or
2) were duplicate publications. Clinical features described
in at least five case studies are reported. Data on study
characteristics, demographic features, clinical manifesta-
tions, ancillary investigations, treatment, and outcome were
systematically scored by DF and MB. Therapy was classified
as first line, second line, or third line therapy. First line
therapy consists of corticosteroid treatment, second line
treatment consists of immunosuppressive therapy with
methotrexate, azathioprine, mycophenolate mofetil, cyclo-
sporine A, or (hydroxyl) chloroquine, and third line
therapy either consists of cyclophosphamide or immuno-
modulatory medication (tumor necrosis factor-alpha inhibi-
tors (TNF-alpha) or B-cell targeted therapy) [3]. Remission
was defined as complete improvement, without residual
symptoms. Favourable outcome was defined as remission,
either complete or incomplete, and no need for alternative
immunosuppressants.
We performed a pooled reanalysis of all published data
in the included studies. Because of heterogeneity be-
tween studies, all data is presented as a number for
which a certain characteristic is present out of the total
number of patients for which it was described (n/N [%])
and a 95% confidence interval (95% CI) was used. For
continuous data the standard deviation (SD) was used.
Heterogeneity between studies was calculated for all
reported variables using the Cochrane Q and I2 statis-
tical tests.
Results
Our search identified 2994 articles of which 29 studies
remained after screening (Fig. 1), including 1088 patients
diagnosed from 1965 to 2015 [6, 8, 9, 11–36]. The num-
ber of patients per study ranged from 5 to 305 patients
(median 27, interquartile range [IQR] 13–37, Additional
file 1: Table S1). The individual study periods varied be-
tween 3 and 31 years (median 13 years, IQR 9–15). Only
one of 29 studies was performed prospectively (3%); [6]
24 of 29 (83%) were single-centre studies [6, 9, 11–19,
21–27, 29–31, 34–36]. Inclusion criteria were described
in 27 of 29 studies (93%) and were based on the Zajicek
criteria in 11 studies [8, 9, 25, 27–31, 33, 35, 36]. Four
studies included patients with definite or probable neu-
rosarcoidosis according to these criteria, and seven in-
cluded definite, probable, or possible neurosarcoidosis
[8, 9, 25, 27–31, 33, 35, 36]. Eleven studies included
biopsy-proven sarcoidosis [6, 11, 14, 16, 18, 20–23, 32,
34]. Five studies included patients with the diagnosis
based on either histological evidence of non-caseating
granulomas or clinical and radiologic findings consistent
with the diagnosis sarcoidosis [13, 15, 17, 19, 24]. Twelve
studies considered only central nervous system involve-
ment of neurosarcoidosis [8, 9, 12, 17, 18, 24, 26–28, 30,
33, 34]. Calculation of the heterogeneity of data reported
in the pooled study results showed significant heterogen-
eity (I2 > 50%) occurred for 48 of 110 studied parameters
(Additional file 1: Table S2 A-C).
Patient characteristics
Neurosarcoidosis was diagnosed in 246 cases of 5263 re-
ported cases of systemic sarcoidosis (5%, range 2–26%)
[6, 13–15, 19, 22, 31]. Mean age at presentation was
43 years (range 11–84 years, SD 11.57, recalculated from
27 studies including 967 patients; Table 1). Overall, 602
of 1088 patients (55%, 95% CI 52–58%) were female.
Ethnicity was reported in 739 patients of which 461 pa-
tients (62%) were Caucasian and 218 patients (29%) were
of African descent. In total 652 patients were diagnosed
according to Zajicek diagnostic criteria: [8, 9] 159 pa-
tients (25%) were classified as having definite neurosar-
coidosis, 371 (59%) as probable neurosarcoidosis and 95
(15%) as possible neurosarcoidosis.
Clinical characteristics
Neurological symptoms were the first clinical manifest-
ation of sarcoidosis in 344 of 662 patients (52%; 95% CI
48–56%). Patients diagnosed with neurosarcoidosis had
a known diagnosis of sarcoidosis outside the nervous
system in 229 of 728 patients (31%, 95% CI 28–35%).
Systemic manifestations of sarcoidosis outside the ner-
vous system at any time during disease course occurred
in 284 of 339 patients (84%; 95% CI 80–88%), consisting
of pulmonary involvement in 338 of 589 patients (57%),
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ocular sarcoidosis in 117 of 589 patients (20%), lymph-
adenopathy in 105 of 589 patients (18%), dermatological
manifestations in 104 of 589 patients (18%) and rheum-
atological manifestations in 104 out of 589 patients
(18%).
The most commonly reported presenting feature of
neurosarcoidosis was cranial neuropathy, which oc-
curred in 572 of 1047 patients (55%, 95% CI 52–58%).
Of all cranial nerves, the facial nerve (24%, 95% CI 21–
27%) and optic nerve (21%, 95% CI 18–24%) were in-
volved most frequently. Other common presenting fea-
tures were headache (32%, 95% CI 28–35%), sensory
abnormalities (29%, 95% CI 24–33%), and motor
symptoms (19%; 95% CI 15–22%) consisting of hemipar-
esis (9%; 95% CI 6–12%) and paraparesis (11%; 95% CI
7–14%). Meningitis was reported in 105 of 648 patients
(16%, 95% CI 13–19%). Spinal cord abnormalities were
reported in 18% (95% CI 15–21%) and involvement of
the peripheral nervous system in 17% of patients (95%
CI 14–21%), mainly consisting of polyneuropathy; myop-
athy was reported in 43 of 288 evaluated patients (15%;
95% CI 11–9%).
Ancillary investigations
Results of CSF analysis were described in 22 studies
(Table 2); a lumbar puncture was performed in the ma-
jority of patients (78%). Pleiocytosis was found in 424 of
730 patients (58%; 95% CI 54–62%), and CSF white cell
counts ranged from 5 to 1571 cells per mm3. CSF total
protein was elevated in 457 of 729 patients (63%, 95% CI
59–66%). The IgG-index was elevated in 36 of 89 evalu-
ated cases (40%, 95% CI 30–51%) with CSF oligoclonal
bands present in 77 of 184 patients (46%, 95% CI 35–
49%). CSF angiotensin-converting enzyme (ACE) levels
were elevated in 189 of 410 patients (46%, 95% CI 41–
51%).
Cranial MRI showed abnormalities in 283 of 362 eval-
uated patients (79%, 95% CI 74–83%), consisting of
Fig. 1 Flow chart of inclusion of studies
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parenchymal lesions in 51% (95% CI 45–56%), and
contrast enhancement of the meninges in 46% (95% CI
42–50%) and of cranial nerves in 26% (95% CI 22–30%).
Spine MRI showed abnormalities in 89 of 185 evaluated
patients (48%; 95% CI 41–55%). Chest X-ray showed
findings consistent with pulmonary or lymph node sar-
coidosis in 277 of 461 patients (60%, 95% CI 56–65%)
and chest CT in 93 of 132 patients (70%, 95% CI 63–
78%). Gallium-67-scintigraphy findings were consistent
with sarcoidosis in 96 of 140 patients (69%, 95% CI 61–
76%). Whole body 18FDG-PET CT, reported in only one
study, was performed in 19 of 52 patients and showed
abnormalities consistent with sarcoidosis in 15 patients
(78%, 95% CI 57–93%).
Serum ACE level was elevated in 238 of 674 patients
(35%, 95% CI 32–39%), erythrocyte sedimentation rate
was elevated in 64 of 202 patients (32%, 95% CI 25–
38%), and hypercalcemia was present in 19 of 222
Table 1 Patient Characteristics
Characteristic n/Na (%) Characteristic n/Na (%)
Age, yr., meanb(SD) 43.1 (11.57) Neurological symptoms
Sex, male 486/1088 (45) Headache 271/860 (32)
Ethnicity Sensory abnormalities 138/484 (29)
Caucasian 461/739 (62) Hypaesthesia 39/174 (22)
African 218/739 (29) Paraesthesia 69/334 (21)
Other 27/739 (4) Neuropathic pain 25/216 (12)
Unknown 33/739 (4) Gait abnormalities 128/466 (28)
Presentation of disease Visual impairment 105/450 (23)
History of sarcoidosis 229/728 (31) Fatigue 47/202 (23)
Systemic sarcoidosis at admission 256/440 (58) Motor abnormalities 103/552 (19)
Primary neurological presentation 344/662 (52) Hemiparesis 41/454 (9)
Isolated neurosarcoidosis 169/770 (22) Paraparesis 37/348 (11)
Systemic involvement Ataxia 64/387 (17)
Pulmonary 316/469 (67) Vertigo 39/277 (14)
Eye 117/469 (25) Hearing impairment 97/716 (14)
Dermatological 99/469 (21) Seizures 132/965 (14)
Rheumatological 99/469 (21) Nausea 11/84 (13)
Otorhinolaryngeal 43/469 (9) Diplopia 41/361 (11)
Hepatic 37/469 (8) Micturition abnormalities 23/206 (11)
Cardial 26/469 (6) Dysarthria 36/413 (9)
Constitutional symptoms 106/469 (23) Dysphagia 44/481 (9)
Cranial nerve palsy 572/1047 (55) Psychiatric symptoms 30/390 (8)
n. VII palsy 227/937 (24) Nystagmus 11/172 (6)
n. II palsy 190/910 (21) Papilledema 23/354 (6)
n. V palsy 111/942 (12) Site of neurological involvement
n. VIII palsy 102/914 (11) Spinal cord disease 98/543 (18)
n. VI palsy 63/906 (7) Peripheral neuropathy 97/558 (17)
n. III palsy 46/869 (5) Polyneuropathy 56/487 (11)
n. IX–X palsy 32/882 (4) (Multiple Mononeuropathies) 16/137 (12)
n. I palsy 17/889 (2) Radiculopathy 7/140 (5)
n. IV palsy 17/869 (2) Meningitis 105/648 (16)
n. XI palsy 5/882 (1) Myopathy 43/288 (15)
n. XII palsy 12/882 (1) Neuro-endocrinec 90/1034 (9)
>1 cranial nerve involved 206/724 (28) Hydrocephalus 52/570 (9)
a n/N: number for which a certain characteristic is present out of the total number of patients for which it was described
b The mean age was recalculated from averages presented in 27 studies (967 patients)
c Panhypopituirism (n = 34), Diabetes insipidus (n = 21), amenorrhea (n = 5), hypothermia/hypotension (n = 1), galactorrhoea (n = 1), not further specified (n = 28)
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evaluated patients (9%, 95% CI 5–12%). A Kveim test
was performed in eight studies, and was reported posi-
tive in 93 of 117 patients (79%, 95% CI 72–87%).
Treatment
The treatment strategies are reported in Table 3. No im-
munosuppressive treatment was indicated in 99 of 655
patients (15%, 95% CI 12–18%). First line therapy, con-
sisting of corticosteroids, was initiated in 434 of 539 pa-
tients (81%, 95% CI 77–84%); subsequently, 24% of these
patients were switched from first line to second or third
line therapy. Second line therapy, consisting of metho-
trexate, azathioprine, (hydroxyl) chloroquine, mycophe-
nolate mofetil, and cyclosporine A, was initiated in 144
of 539 patients (27%, 95% CI 23–31%). Third line ther-
apy, consisting of cyclophosphamide and TNF-alpha an-
tagonists, was initiated in 49 of 539 patients (9%, 95% CI
7–12%). Overall, 546 of 655 patients (83%, 95% CI 80–
86%) were treated with corticosteroids, either as mono-
therapy or combination therapy with a second or third
line agent; methotrexate was administered in 16% (CI
13–19%), azathioprine in 8% (95% CI 6–10%), cyclo-
phosphamide in 6% (95% CI 4–8%), and TNF-alpha an-
tagonists in 4% (95% CI 2–5%). The use of TNF-alpha
antagonists increased over time (Fig. 2). Other reported
treatments consisted of neurosurgical intervention in 30
of 230 patients (13%, 95% CI 9–17%), hormonal substi-
tution therapy in 18 of 227 patients (8%, 95% CI 4–
12%), and anti-epileptic medication in 14 of 99 patients
(14%, 95% CI 7–21%).
Outcome
Treatment response is reported in Table 3. The average
time of follow-up was 4 years (IQR 2–7, SD 4.4). Mortal-
ity was reported in 23 of 29 studies (79%), ranging from
0 to 33%. Overall, 42 of 826 patients died (5%; 95% CI
4–7%). The temporal trend of patients with neuro-
sarcoidosis with reported substantial improvement is
noted in Fig. 3. Total remission was achieved in 126 of
465 patients (27%, 95% CI 23–31%), incomplete remission
in 147 of 465 (32%, 95% CI 27–36%), stable disease in 111
of 465 (24%; 95% CI 20–28%), and deterioration in 28 of
465 patients (6%; 95% CI 4–8%). Favourable outcome was
reported in 161 out of 227 patients (71%; 95% CI 65–77%)
who received only first line treatment. Favourable out-
come was reported in 47 of 85 patients (55%; 95% CI 45–
66%) who received second line therapy and were not
switched to third line therapy. Seven out of 18 patients
(39%; 95% CI 16–62%) who received third line therapy
had a favourable outcome.
Discussion
Our data show that neurosarcoidosis is a diverse illness,
with heterogeneous clinical presentation, varying results of
ancillary investigation, and considerable inter-individual dif-
ferences in treatment response. Four clinical presentations
Table 2 Ancillary investigations on presentation
Characteristic n/Na (%) Characteristic n/Na (%)
Blood chemical tests Abnormal ancillary investigation
Serum ACE increasedb 238/674 (35) Chest X-ray 277/461 (60)
Serum calcium increasedb 19/222 (9) Chest CT 93/132 (70)
ESR >20 mm/h 64/202 (32) Gallium-67 scintigraphy 81/123 (66)
Cranial CT 83/168 (49)
Cerebrospinal fluid analysis Cranial MRI 283/362 (78)
Lumbar puncture performed 774/988 (78) Parenchymal lesions 191/378 (51)
White cell count (cells/mm3) 5–1571 Meningeal enhancement 282/610 (46)
>5 cells/mm3 424/730 (58) Mass lesions 82/501 (16)
Protein (g/L) 0.45–22.4 Cranial nerve enhancement 123/478 (26)
>0.45 g/Lc 457/729 (63) Spinal MRI 89/185 (48)
Hypoglycorrhachiac 43/312 (14) Diagnosis
Increased IgG-indexc 36/89 (40) Histopathological confirmationd 455/550 (81)
Oligoclonal bands present 77/184 (42) Definite neurosarcoidosis 159/625 (25)
Increased CSF ACEc 189/410 (46) Probable neurosarcoidosis 371/625 (59)
Normal 90/332 (27) Possible neurosarcoidosis 95/625 (15)
a n/N: number for which a certain characteristic is present out of the total number of patients for which it was described
b As reported in articles. The normal values of serum calcium were not reported in studies. The normal values of serum ACE varied between > 52 IU/L
and >100 IU/L
c As reported in the articles. The normal values of CSF glucose, CSF IgG index and CSF ACE varied between studies (CSF glucose between <35 mg/dL and
<0.50 mg/dL, IgG index between >0.6 and >0.7 and CSF ACE between > 1U/L and 3 U/L)
d Total histopathological confirmation, either in the CNS or systemic disease
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could be distilled from our meta-analysis: those presenting
with cranial neuropathy, spinal cord inflammation, periph-
eral neuropathy or myopathy, or (chronic) meningitis.
Neurological symptoms were the first clinical manifestation
of sarcoidosis in about half of patients, and of those known
with sarcoidosis about 5% eventually develop neurosarcoi-
dosis. Although new treatments, such as TNF-alpha antag-
onists, are increasingly used, the mortality rate among
patients with neurosarcoidosis remains 5% and about one
third does not have a substantial clinical improvement on
treatment.
Our systematic review and meta-analysis has limita-
tions. First, all but one study were retrospective, introdu-
cing selection bias. This limits the external validity of
our results and may overestimate effect of treatment in
this disease. Second, most studies were performed in ter-
tiary referral centres in European countries or the USA,
which is also reflected in the ethnicity of included pa-
tients, again introducing selection bias. Tertiary care pa-
tients might be more severely affected and perhaps less
responsive to treatment. Third, studies used heteroge-
neous inclusion criteria and not all items were reported
for all patients. Fourth, patients were included over a
period of 30 years. Within this time period, alternative
diagnoses mimicking neurosarcoidosis have been de-
scribed which previously would be classified as probable
or even definite neurosarcoidosis. Examples of such
mimics are IgG4-related disease or the POEMS syn-
drome [37–39]. These rare diseases may present with
similar clinical features and histopathology. It may well
Table 3 Treatment and outcome
Characteristic n/Na (%) Characteristic n/Na (%)
No treatment 99/655 (15) Other treatment modalities
First line therapy 434/539 (81) Neurosurgical intervention 30/230 (13)
Second line therapy 144/539 (27) Anti-epileptic medication 14/106 (13)
Third line therapy 49/539 (9) Hormonal substitution 18/227 (8)
Overall treatment Follow-up, yr., mean (SD) 4.4 (SD 3.15)
Corticosteroids 546/655 (83) Outcome
Methotrexate 105/655 (16) Remission 126/415 (27)
Azathioprine 54/655 (8) Improvement 147/415 (32)
(Hydroxy) chloroquine 24/655 (4) Stable disease 100/415 (22)
Mycophenolate mofetil 12/655 (2) Deterioration 19/415 (4)
Cyclosporine A 10/655 (2) Mortality 42/826 (5)
Cyclophosphamide 40/655 (6)
TNF-alpha antagonists 24/655 (4) Favourable outcome per treatment group
Treatment switches First line therapy 161/227 (71)
First to second or third line 88/363 (24) Second line therapy 47/85 (55)
Second to third line 14/104 (13) Third line therapy 7/18 (39)
Between third line 7/23 (30)
a n/N: number for which a certain characteristic is present out of the total number of patients for which it was described
Fig. 2 Proportion of treatment used according to timeframe
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be that different aetiologies may exist for a disease that
we now call neurosarcoidosis. Finally, when performing
the meta-analyses we found there frequently was
significant heterogeneity between studies on the re-
ported data. This confirms the influence of the above-
mentioned biases.
Making a diagnosis of neurosarcoidosis can be diffi-
cult. A definite diagnosis was made only in one out of
four patients. The far majority of patients were classified
as probable neurosarcoidosis. Diagnostic classification
for neurosarcoidosis includes MRI, CSF and serum in-
flammatory markers, FDG-PET, gallium scan, and chest
imaging [10]. Our study shows that none of these diag-
nostic markers seems to have a good accuracy for the
diagnosis. Multicentre prospective diagnostic studies in
patients with suspected neurosarcoidosis are needed to
test diagnostic accuracy of these tests in the diagnostic
process. These studies should determine the value of
markers noted in the diagnostic criteria as well as other
promising new markers, such as soluble interleukin-2-
receptor [35, 40].
Clear guidance for the treatment of patients with neu-
rosarcoidosis is lacking. Most treatment strategies are
extrapolated from few studies on pulmonary sarcoidosis.
In our meta-analysis 83% of patients received corticoste-
roids, which can be considered the mainstay of treat-
ment in neurosarcoidosis. However, 24% of the patients
initially treated with first line therapy were switched to
second or third line therapy. In addition, corticosteroid-
associated side effects occur frequently and can be se-
vere [8, 20]. Over time, second and third line therapy
emerged into the treatment of neurosarcoidosis, most
recently TNF-alpha antagonists. Value of TNF-alpha an-
tagonists has been suggested only in a phase II rando-
mised controlled trial (RCT) in pulmonary sarcoidosis
[41]. This trial including 138 patients showed that
infliximab therapy resulted in a statistically significant
improvement in percentage of predicted forced vital cap-
acity at week 24. The value of TNF-alpha antagonists is
based on sporadic case series, and it is unclear if patients
benefit from a combined therapy of TNF-alpha antago-
nists and first and second line therapy. It is also unclear
for how long TNF-alpha antagonists should be contin-
ued and whether this therapy is associated with side
effects. RCTs on treatments or treatment strategies in
this disease are urgently needed.
Conclusions
Neurosarcoidosis develops in 5% of the sarcoidosis
patients, and in more than half of these patients neuro-
logical symptoms are the primary presentation of sarcoid-
osis. The diagnosis is difficult due to the heterogeneous
clinical presentation and low sensitivity of ancillary inves-
tigations. Despite the increasing use of second and third
line medication, still one-third of patients do not improve
or deteriorate. These data stress the need for prospective
cohort studies and treatment trials.
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